Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00433290 · ClinicalTrials.gov registry record · Phase 3

Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain

A Phase 3 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
256
Enrollment target

NCT00433290: Completed Phase 3 study, sponsored by Eli Lilly and Company.

NCT00433290 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 256 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00433290, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
256 participants
Enrollment target

Study Summary

The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

Primary Outcome

A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Changes are timepoint minus baseline.

Interventions

  • DRUG Placebo
  • DRUG Duloxetine

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2007-02
Est. Completion 2008-05
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What the finished NCT00433290 record still lists

NCT00433290 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00433290 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00433290 about?

NCT00433290 is a clinical study titled "Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain". The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

What is the current status of trial NCT00433290?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2007-02. Estimated completion is 2008-05.

What interventions are being tested in trial NCT00433290?

The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).

Who is sponsoring clinical trial NCT00433290?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00433290's enrollment target sits among peer trials

256 1240th of 2000 higher than 759 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02464696 · 256 participants · NA

    Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

  • NCT03793062 · 256 participants

    Genetic and Epigenetic Basis of Chronic Wounds

  • NCT04322318 · 256 participants · Phase 2

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • NCT04468360 · 256 participants · Phase 2

    Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00433290, the US trial registry maintained by the National Library of Medicine. NCT00433290 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.